Hormone replacement therapy and WONCA/COOP functional status: A cross-sectional population-based study of women in Israel

Climacteric

Volumn 8, Issue 2, 2005, Pages 171-176

  Cohen, O ^a   Vinker, S ^a   Yaphe, J ^a   Kitai, E ^a  

^a NONE

Author keywords

Daily activities; Functional status; Hormone replacement therapy; Israel; Menopause

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; AGED; FEMALE; HEALTH STATUS; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; MENOPAUSE; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SYMPTOMATOLOGY; TREATMENT INDICATION; TREATMENT OUTCOME;

AGED; CROSS-SECTIONAL STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEALTH STATUS; HUMANS; ISRAEL; MENOPAUSE; MIDDLE AGED; PRIMARY HEALTH CARE; QUESTIONNAIRES; REGRESSION ANALYSIS;

EID: 20844449887     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/13697130500118019     Document Type: Review

References (17)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
2. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57
3. Ballinger CB. Psychiatry, morbidity and the menopause. BMJ 1975;3:344-6
4. Barlow DH, Grosset KH, Hart H, Hart DM. A study of the experience of Glasgow women in the climacteric years. Br J Obstet Gynaecol 1989;96:1192-7
5. Jaszman L. Epidemiology of the climacteric complaints. Horm Res 1973;2:220-34
6. Hunter MS. Somatic experience of the menopause: a prospective study. Psychosom Med 1979;52;357-67
7. Nelson E, Wasson J, Kirk J, et al. Assessment of function in routine clinical practice: Description of the COOP Chart Method and preliminary findings. J Chron Dis 1987;40(Suppl 1):55-63s
8. Kinnersley P, Peters T, Stott N. Measuring functional health status in primary care using the COOP-WONCA charts: acceptability, range of scores, construct validity, reliability and sensitivity to change. Br J General Pract 1994;44:545-9
9. Yodfat Y. Functional status in treatment of heart failure by captopril: a multicenter controlled double blind study in family practice. Family Pract 1991;8:409-11
10. Yodfat Y. A multicentre study of lisinopril in the treatment of mild to moderate hypertension. Harefuah 1995;129:26-9,78
11. Limouzin-Lamothe MA, Mairon N, Joyce CRB, LeGal M. Quality of life after the menopause: influence of hormonal replacement therapy. Am J Obstet Gynecol 1994;170:618-24
12. Matthews KA, Kuller LH, Wing RK, Meilahn EN, Plantinga P. Prior use of estrogen replacement therapy, are users healthier than nonusers? Am J Epidemiol 1996;143:971-8
13. Wilson DH, Taylor AW, MacLennan AH. Health status of hormone replacement therapy users and non-users as determined by the SF-36 quality of life dimension. Climacteric 1998;1:50-4
14. MacLennan AH, Wilson DH, Taylor AW. Hormone replacement therapy: prevalence, compliance and the 'healthy women' notion. Climacteric 1998;1:42-9
15. Jenkinson C, Lawrence K, McWhinnie D, Gordon J. Sensitivity to change of health status measures in a randomised controlled trial: comparison of the COOP charts and the SF-36. Quality of Life Res 1995;4:47-52
16. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA. Quality of life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA 2002;287:591-7
17. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2003;348:645-50